Accreditation Information

Direct Accreditation:

Boston University School of Medicine is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians. 

Boston University School of Medicine designates this live activity for a maximum of 1.5 AMA PRA Category Credit(s)™.  Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Objectives

Explain the complex symptoms of Amyloidosis
Facilitate multidisciplinary care for patients with amyloidosis disease
Screen amyloidosis patients for clinical trials
Discuss current amyloidosis research

Target Audience

The primary target audience for this activity is the amyloidosis center clinical team as well as respective fellows and residents.

Faculty Disclosure

Faculty, Planning Committee and CME Administrator disclosure statement:

Vaishali Sanchorawala, Speaker, Course Director and Planning Committee, receives support from Proclara and Caelum as an Scientific advisor, receives Research grant from Janssen  and Celgene, receives Grant support from Takeda.

John Berk, Speaker, Co-Course director and Planning Committee, receives support as Research Study Site Investigator, Scientific Advisor and Invited Lecturer at Alnylam Pharmaceuticals, Akcea Therapeutics, Intellia Therapeutics, Corino Therapeutics and Pfizer Pharmaceuticals companies.

Shayna Sarosiek, Co-Course director, funded for clinical trial from Spectrum/Acrotech.

Daniel Alford, Co-Course Director, has no relevant financial relationships to disclose.

Sakina Flint, Program Manager, has no relevant financial relationships to disclose.

Faculty disclosure of off-label use:

Faculty members plan on discussing drugs in the treatment of AL amyloidosis that non-approved by FDA, diflunisal, doxycycline, green tea extract for inhibition of ATTR disease progression.

Faculty disclosure policy:

Boston University School of Medicine asks all individuals, and their spouses/partners, involved in the development and presentation of Continuing Medical Education (CME) and Continuing Nursing Education (CNE) activities to disclose all relevant financial relationships with commercial interests. This information is disclosed to CME activity participants prior to the start of the educational activity. Boston University School of Medicine has procedures to resolve all conflicts of interest. In addition, faculty members are asked to disclose when any unapproved use of pharmaceuticals and devices is being discussed.